The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity of third line (3L) therapy in patients with metastatic non-clear-cell renal cell carcinoma (mnccRCC).
 
Annalisa Guida
No Relationships to Disclose
 
Gwénaël Le Teuff
No Relationships to Disclose
 
Emeline Colomba
No Relationships to Disclose
 
Carolina Alveosta Silva
No Relationships to Disclose
 
Flore Salviat
No Relationships to Disclose
 
Giulia Baciarello
No Relationships to Disclose
 
Lisa Derosa
No Relationships to Disclose
 
Yohann Loriot
No Relationships to Disclose
 
Karim Fizazi
Honoraria - Amgen; Astellas Pharma; Janssen; Merck; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Curevac; ESSA; Janssen Oncology; Orion; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Amgen
 
Mario Di Palma
No Relationships to Disclose
 
Christophe Massard
No Relationships to Disclose
 
Bernard Escudier
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EUSA Pharma; Exelixis; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Laurence Albiges
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Ipsen (Inst); Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Roche (Inst); Sanofi